
    
      Investigator and Study Center:

      Judy Tong, OD Eye Care Center Southern California College of Optometry

      Test Product, Dose and Mode of Administration:

      Bepreve (bepotastine besilate ophthalmic solution) 1.5% bid ou vs. Alrex (loteprednol
      etabonate ophthalmic suspension) 0.2% qid ou

      Study Title:

      A Single-Center, Masked, Randomized Study Comparing Bepreve (bepotastine besilate) 1.5% - H1
      Specific Antihistamine vs. Alrex (loteprednol etabonate) 0.2% - Corticosteroid in Subjects
      with Moderate to Severe Allergic Conjunctivitis

      Primary Objective(s):

      The primary objective of this study is to compare the efficacy of Bepreve (bepotastine
      besilate) 1.5% ophthalmic solution compared to Alrex (loteprednol etabonate) 0.2% in the
      treatment of moderate to severe allergic conjunctivitis in patients over the age of 18 years
      of age

      Study Design:

      Interventional, Randomized, Parallel Arm, Investigator Masked

      Study Population:

      Subjects over the age of 18 years of age with moderate to severe allergic conjunctivitis.

      Duration of Treatment: 14 days

      Efficacy Assessments: Itching, Bulbar conjunctival injection, Bulbar conjunctival chemosis

      Safety Assessments: N/A
    
  